Table 1.
Aptamers in clinic
| Name | Company | Target | Indication | Phase | References |
|---|---|---|---|---|---|
| Macugen | Pfizer/Eyetech | VEGF | AMD | Approved | Ng et al. (2006) |
| AS1411 | Antisoma | Nucleolin | Cancer | Phase II | Mongelard & Bouvet (2010) and Bates et al. (2009) |
| REG1 | Regado | Factor IXa | ACS | Phase II | Rusconi et al. (2002) and Povsic et al. (2011) |
| ARC1779 | Archemix | vWF | TTP | Phase II | Jilma-Stohlawetz et al. (2011) |
| NU172 | ARCA | Thrombin | CABG | Phase II | Keefe et al. (2010) |
| E10030 | Ophthotech | PDGF | AMD | Phase II | Akiyama et al. (2006) |
| ARC1905 | Ophthotech | C5 | AMD | Phase I | Biesecker et al. (1999) |
| NOX-E36 | NOXXON | MCP-1 | DN | Phase I | Maasch et al. (2008) and Darisipudi et al. (2011) |
| NOX-A12 | NOXXON | SDF-1 | Cancer | Phase I | Darisipudi et al. (2011) and Duda et al. (2011) |
| NOX-H94 | NOXXON | Hepcidin | Anemia | Phase I | |
| BAX499/ARC19499 | Baxter/Archemix | TFPI | Hemophilia | Phase I | Waters et al. (2011) and Parunov et al. (2011) |
AMD, age-related macular degeneration; ACS, acute coronary syndrome. TTP, thrombotic thrombocytopenic purpura; CABG, coronary artery bypass grafting; DN, diabetic nephropathy.